Drugs / Anti-mesothelin CAR-T cells
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05783089 | Apr 2023 → Apr 2025 overdue | cancer or benign tumor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05531708 | Apr 2021 → Apr 2025 | — | Shanghai Pudong Hospital | Withdrawn | No outcome recorded |
| Phase 1 | NCT03545815 | Mar 2018 → Oct 2020 | cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02930993 | Aug 2016 → Aug 2018 | cancer or benign tumor | China Meitan General Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07010523 | Oct 2024 → Oct 2026 expected | neoplasm | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-mesothelin CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03545815 ↗ |
| Modality | Cell therapy | “autologous T cells engineered to express chimeric antigen receptor targeting mesothelin” NCT02930993 ↗ |
| Route | Intravenous | “intravenously infused with anti-mesothelin CAR T cells” NCT02930993 ↗ |
| Target | MSLN | “Anti-MSLN CAR-T cell injection” NCT07010523 ↗ |